InflaRx N.V. (IFRX)

Market Cap	77.07M
Revenue (ttm)	171,642
Net Income (ttm)	-47.69M
Shares Out	67.60M
EPS (ttm)	-0.81
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	82,940
Open	1.040
Previous Close	1.060
Day's Range	1.020 - 1.150
52-Week Range	0.824 - 2.815
Beta	2.22
Analysts	Strong Buy
Price Target	9.00 (+689.47%)
Earnings Date	May 7, 2025

About IFRX

InflaRx N.V., a clinical-stage biopharmaceutical company, discovers and develops inhibitors using C5a technology in Germany and the United States. The company’s C5a is an inflammatory mediator that is involved in the progression of a variety of autoimmune and other inflammatory diseases. Its lead product candidate is vilobelimab, a novel intravenously delivered first-in-class anti-C5a monoclonal antibody, which completed the Phase III clinical trial for the treatment of hidradenitis suppurativa, a rare and chronic debilitating systemic inflamma...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Nov 8, 2017
• Employees: 74
• Stock Exchange: NASDAQ
• Ticker Symbol: IFRX
• Website: https://www.inflarx.de

Financial Performance

In 2024, InflaRx's revenue was 165,789, an increase of 162.79% compared to the previous year's 63,089. Losses were -46.06 million, 7.96% more than in 2023.

Financial numbers in EUR

Analyst Forecast

According to 2 analysts, the average rating for IFRX stock is "Strong Buy." The 12-month stock price forecast is $9.0, which is an increase of 689.47% from the latest price.

Price Target

$9.0

(689.47% upside)

Analyst Consensus: Strong Buy